1. Home
  2. LQDA vs USAC Comparison

LQDA vs USAC Comparison

Compare LQDA & USAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • USAC
  • Stock Information
  • Founded
  • LQDA 2004
  • USAC 1998
  • Country
  • LQDA United States
  • USAC United States
  • Employees
  • LQDA N/A
  • USAC N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • USAC Natural Gas Distribution
  • Sector
  • LQDA Health Care
  • USAC Utilities
  • Exchange
  • LQDA Nasdaq
  • USAC Nasdaq
  • Market Cap
  • LQDA 2.5B
  • USAC 2.9B
  • IPO Year
  • LQDA 2018
  • USAC N/A
  • Fundamental
  • Price
  • LQDA $32.15
  • USAC $24.28
  • Analyst Decision
  • LQDA Strong Buy
  • USAC Hold
  • Analyst Count
  • LQDA 10
  • USAC 4
  • Target Price
  • LQDA $37.40
  • USAC $25.50
  • AVG Volume (30 Days)
  • LQDA 2.7M
  • USAC 276.0K
  • Earning Date
  • LQDA 11-03-2025
  • USAC 11-05-2025
  • Dividend Yield
  • LQDA N/A
  • USAC 8.55%
  • EPS Growth
  • LQDA N/A
  • USAC 43.67
  • EPS
  • LQDA N/A
  • USAC 0.81
  • Revenue
  • LQDA $69,216,000.00
  • USAC $991,507,000.00
  • Revenue This Year
  • LQDA $424.31
  • USAC $7.32
  • Revenue Next Year
  • LQDA $359.32
  • USAC $4.51
  • P/E Ratio
  • LQDA N/A
  • USAC $30.35
  • Revenue Growth
  • LQDA 343.41
  • USAC 6.66
  • 52 Week Low
  • LQDA $10.37
  • USAC $21.53
  • 52 Week High
  • LQDA $32.41
  • USAC $30.10
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 70.67
  • USAC 61.33
  • Support Level
  • LQDA $27.76
  • USAC $23.40
  • Resistance Level
  • LQDA $30.50
  • USAC $24.30
  • Average True Range (ATR)
  • LQDA 1.85
  • USAC 0.69
  • MACD
  • LQDA 0.36
  • USAC 0.10
  • Stochastic Oscillator
  • LQDA 98.23
  • USAC 100.00

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About USAC USA Compression Partners LP Common Units Representing Limited Partner Interests

USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services in several shale plays throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.

Share on Social Networks: